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MATERIALS & METHODS
The indiscriminate use of antibiotics and chemotherapeutic agents and the genetic ability of bacteria to transmit and acquire resistance resulted in the
development of resistant species. In the last few years, several studies have been conducted in different countries to demonstrate the efficacy of natural products, not
only studying their direct antimicrobial activity but also their capacity as resistance-modifying agents. The main objective of the present work was to evaluate the
capacity of five wild mushroom extracts to potentiate the action of standard antibiotics, through synergisms that allow a decrease in their therapeutic doses and
ultimately contribute to the reduction of resistances.
INTRODUCTION
RESULTS & DISCUSSION
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Mushroom species: Five mushroom species (Fistulina hepatica, Leucopaxillus giganteus, Mycena
rosea, Russula delica, Sarcodon imbricatum) were collected in different ecosystems of the Trás-
os-Montes region in the northeast of Portugal.
Microorganisms tested: Clinical isolates from patients hospitalized in various departments
of the Hospital Center of Trás-os-Montes and Alto Douro – Chaves, Portugal.
Gram negative bacteria: Escherichia coli with different antibiotic resistance proflile E. coli 1
(resistant to Ampicillin, Ciprofloxacin and Trimethoprim/ Sulfamethoxazole), E. coli 2
(resistant to Amoxicillin/Clavulanic acid and Ampicillin) and E. coli ESBL (resistant to
Ampicillin, Nalidixic acid, Norfloxacin, Ciprofloxacin, Cephalosporins and
Trimethoprim/Sulfamethoxazole) , isolated from urine.
Gram positive bacteria: MRSA (resistant to beta-lactams − Penicillin Ampicillin, Cefoxitin,
but also to Quinolones − Ciprofloxacin and Levofloxacin) isolated from wound exudates;
All strains were identified using the MicroScan® panels automated methodology - Siemens.
Antimicrobial activity methology: Microdilution method and
p-iodonitrotetrazolium chloride (INT) colorimetric assay.
MIC determination: The MIC of the samples were detected following addition of INT
(0.2 mg/ml, 40 µl) and incubation at 37ºC for 30 min. Viable microorganisms reduced the
yellow dye to a pink colour. MIC was defined as the lowest sample concentration that
prevented the color change of the medium and exhibited an inhibition of microbial growth
Sinergistic Effect: Fractional inhibitory concentration (FIC) was calculated according to
the equation: MIC(antibiotic+extract/MICantibiotic). The interpretations were made as
follows: synergistic (S; <0.5), indifferent (I; 0.5 to 4), or antagonistic (A; >4). All the assays
were carried out in duplicate.
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Table 2: Effect of  antibiotics individually and in combination with different mushroom extracts in Escherichia coli 1
Table 1:  Effect of  antibiotics individually and in combination with different mushroom extracts in MRSA (Methicillin-
resistant Staphylococcus aureus).
Table 3. Effect of  antibiotics individually and in combination with different mushroom extracts in Escherichia coli 2.
Antibiotic Antibiotic
100%
MIC
Antibiotic 60% with F. 
hepatica MIC/FIC (Effect)
Antibiotic 40% with F. 
hepatica MIC/FIC (Effect)
Antibiotic 60% with M. 
rosea
MIC/FIC (Effect)
Antibiotic 40% with M. rosea 
MIC/FIC (Effect)
Ampicillin 8 2.4/0.3 (S) 1.6/0.2 (S) 2.4/0.3 (S) 1.6/0.2 (S)
Cefoxitin 4 1.2/0.3 (S) 0.8/0.2 (S) 0.6/0.15 (S) 0.2/0.05 (S)
Ciprofloxacin 2 0.6/0.3 (S) 0.4/0.2 (S) 0.6/0.3 (S) 0.4/0.2 (S)
Levofloxacin 4 1.2/0.3 (S) 0.8/0.2 (S) 2.4/0.6 (I) 0.8/0.2 (S)
Penincillin 8 2.4/0.3 (S) 1.6/0.2 (S) 2.4/0.3 (S) 0.8/0.1 (S)
Antibiotic Antibiotic 
100%
MIC
Antibiotic 60% with R. 
delica
MIC/FIC (Effect)
Antibiotic 40% with R. 
delica MIC/FIC (Effect)
Antibiotic 60% with S. 
imbricatum MIC/FIC 
(Effect)
Antibiotic 40% with S. 
imbricatum
MIC/FIC (Effect)
Ampicillin 8 4.8/0.6 (I) 3.2/0.4 (S) >4.8 >3.2
Cefoxitin 4 1.2/0.3 (S) 0.4/0.1 (S) nt nt
Ciprofloxacin 2 >1.2 >0.8 >1.2 >0.8
Levofloxacin 4 1.2/0.3 (S) 0.8/0.2 (S) 0.6/0.15 (S) 0.4/0.1 (S)
Penincillin 8 4.8/0.6 (I) 1.6/0.2 (S) >4.8 >3.2
Antibiotic
Antibiotic 
100%
MIC
Antibiotic 60% with 
F. hepatica
MIC/FIC (Effect)
Antibiotic 40% with 
F. hepatica
MIC/FIC (Effect)
Antibiotic 60% with 
L. giganteus
MIC/FIC (Effect)
Antibiotic 40% 
with L. giganteus
MIC/FIC (Effect)
Ampicillin 16 9.6/0.6 (I) 6.4/0.4 (S) 4.8/0.3 (S) 0.8/0.05 (S)
Amoxicillin/Clavulanic acid 16 >9.6 >6.4 >9.6 6.4/0.4 (S)
Ciprofloxacin 2 nt nt nt nt
Trimethoprim/Sulfamethoxazole 76 nt nt nt nt
Antibiotic Antibiotic 
100%
MIC
Antibiotic 60% with 
R. delica
MIC/FIC (Effect)
Antibiotic 40% with 
R. delica MIC/FIC 
(Effect)
Ampicillin 16 9.6/0.6 (I) 3.2/0.2 (S)
Amoxicillin/Clavulanic acid 16 9.6/0.6 (I) 3.2/0.2 (S)
Ciprofloxacin 2 nt nt
Trimethoprim/Sulfamethoxazole 76 Nt nt
Antibiotic Antibiotic 
100%
MIC
Antibiotic 60% with 
F. hepatica
MIC/FIC (Effect)
Antibiotic 40% with 
F. hepatica
MIC/FIC (Effect)
Antibiotic 60% with 
L. giganteus
MIC/FIC (Effect)
Antibiotic 40% with 
L. giganteus
MIC/FIC (Effect)
Ampicillin 16 nt nt >9.6 >6.4
Amoxicillin/Clavulanic acid 16 nt nt nt nt
Ciprofloxacin 2 nt nt >1.2 >0.8
Trimethoprim/Sulfamethoxazole 76 nt nt >45.6 >30.4
Antibiotic Antibiotic 
100%
MIC
Antibiotic 60% with 
R. delica
MIC/FIC (Effect)
Antibiotic 40% with 
R. delica MIC/FIC 
(Effect)
Ampicillin 16 4.8/0.3 (S) 1.6/ 0.1 (S)
Amoxicillin/Clavulanic acid 16 nt nt
Ciprofloxacin 2 0.6/0.3 (S) 0.2/0.1 (S)
Trimethoprim/Sulfamethoxazole 76 45.6/0.6 (I) 15.2/0.2 (S)
Table 4. Effect of  antibiotics individually and in combination with different mushroom extracts in Extended-
spectrum beta-lactamase-producing (ESBL) Escherichia coli.
Antibiotic Antibiotic 
100%
MIC
Antibiotic 60% with F. 
hepatica MIC/FIC 
(Effect)
Antibiotic 40% with F. 
hepatica MIC/FIC 
(Effect)
Antibiotic 60% with L. 
giganteus
MIC/FIC (Effect)
Antibiotic 40% with L. 
giganteus
MIC/FIC (Effect)
Ampicillin 16 >9.6 >6.4 4.8/0.3 (S) 3.2/0.2 (S)
Amoxicillin/Clavulani
c acid 16 nt nt nt nt
Ciprofloxacin 2 >1.2 >0.8 1.2/0.6 (I) 0.4/0.2 (S)
Trimethoprim/Sulfam
ethoxazole 76 >45.6 >30.4 22.8/0.3 (S) 15.2/0.2 (S)
Antibiotic Antibiotic 
100%
MIC
Antibiotic 60% with R. 
delica
MIC/FIC (Effect)
Antibiotic 40% with R. 
delica MIC/FIC (Effect)
Ampicillin 16 4.8/0.3 (S) 1.6/0.1 (S)
Amoxicillin/Clavulani
c acid 16 nt nt
Ciprofloxacin 2 0.6/0.3 (S) 0.2/0.1 (S)
Trimethoprim/Sulfam
ethoxazole 76 22.8/0.3 (S) 7.6/0.1 (S)
 The results obtained showed higher synergistic effects against MRSA (Table 1) than against
E. coli (Tables 2-4).
 Regarding MRSA (Table 1), Mycena rosea and Fistulina hepatica were the best extracts for
synergistic effects
 Mycena rosea and Fistulina hepatica extracts allowed synergistic effects with quinolones (
ciprofloxacin and levofloxacin)(Table 1).
 It can be observed in all the extracts, an increase of FIC values with the increase of
antibiotic percentage, occurring in some cases an increase of FIC higher than 0.5, and
disappearing the synergistic effect. Nevertheless, for Fistulina hepatica extract, despite the
increase of FIC values with higher antibiotic percentage, the synergism still remains (Table 1).
 Sarcodon imbricatum extract gave the worst results and did not show synergisms with the tested
antibiotics, except for levofloxacin (Table 1).
 The efficiency of Russula delica extract against E. coli (Tables 2 and 3) was notoriously higher
than Leucopaxillus giganteus extract; nevertheless the latter extract showed better synergistic
effects against ESBL E. coli (Table 4).
 Among the three mushroom species, Fistulina hepatica extract gave the lowest synergistic
effect against E. coli (Tables 2 and 3).
 The action of cirpofloxacin was potentiated by Russula delica or Leucopaxillus giganteus extracts
(Tables 3 and 4).
 Russula delica extract was the only one that gave synergistic effects with the antimetabolic
antibiotic trimethoprim/sulfamethoxazole (Tables 3 and 4)
The present study shows that, similarly to plants, some mushroom extracts can
potentiate the action of antibiotics extensively used in clinical practice for Gram-
positive or Gram-negative bacteria, and might be used against multi-resistant bacteria.
CONCLUSIONS
